%0 Journal Article
%T mTOR Inhibition by Everolimus Does Not Impair Closure of Punch Biopsy Wounds in Renal Transplant Patients
%A Anne Costanzo
%A Dianne B. McKay
%A Josephine Gonzales
%A Julie M. Jameson
%A Megan Boyett
%A Peggy P. Han
%A Shelley B. Dutt
%A Steven Steinberg
%J Archive of "Transplantation Direct".
%D 2017
%R 10.1097/TXD.0000000000000663
%X Mammalian target of rapamycin (mTOR) inhibitors are approved to prevent allograft rejection and control malignancy. Unfortunately, they are associated with adverse effects, such as wound healing complications that detract from more extensive use. There is a lack of prospective wound healing studies to monitor patients treated with mTOR inhibitors, such as everolimus or sirolimus, especially in nondiabetics
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381740/